A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

NCT01973309 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Vantictumab combined with paclitaxel

Sponsor

OncoMed Pharmaceuticals, Inc.